Last updated: 11/03/2018 01:01:05
Human Papillomavirus (HPV) vaccine (Cervarix TM) efficacy, immunogenicity & safety trial in adult Japanese women with GSK Biologicals HPV-16/18 vaccine
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A phase II study to assess the efficacy, immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy Japanese female subjects aged 20 - 25 years.
Trial description: Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb). This infection may go away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. This study will evaluate the efficacy in prevention of persistent HPV-16 or HPV-18 cervical infection lasting at least 6 months, the immunogenicity and safety of GSK Biologicals HPV-16/18 vaccine (Cervarix TM ) over 24 months in Japanese adult women aged 20 - 25 years of age at study start. Approximately 1000 study subjects will either receive the HPV vaccine or a control vaccine (Hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of subjects with persistent cervical infection with Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)
Timeframe: Throughout the study period (up to Month 24)
Secondary outcomes:
Number of subjects with incident cervical infection with Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18)
Timeframe: Up to Month 24
Number of subjects with cytologically-confirmed abnormalities concurrently associated with Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus 18 (HPV-18) cervical infection
Timeframe: Up to Month 24
Number of subjects with histopathologically-confirmed lesions concurrently associated with Human Papillomavirus 16 (HPV-16) and/or Human Papillomavirus (HPV-18) cervical infection
Timeframe: Up to Month 24
Number of subjects with incident cervical infection with any oncogenic Human Papillomavirus (HPV) types
Timeframe: Up to Month 24
Number of subjects with persistent cervical infection with any oncogenic Human Papillomavirus (HPV) types
Timeframe: Up to Month 24
Number of subjects with cytologically-confirmed abnormalities concurrently associated with cervical infection with any oncogenic Human Papillomavirus (HPV) type
Timeframe: Up to Month 24
Number of subjects with histopathologically confirmed lesions concurrently associated with cervical infection with any oncogenic Human Papillomavirus (HPV) type
Timeframe: Up to Month 24
Number of subjects with anti-human papillomavirus 16 and 18 (anti-HPV-16 and anti-HPV-18) antibody titers above the cut-off value
Timeframe: At Months 0 (pre-vaccination), 6, 7, 12, 18 and 24
Titers of anti-human Papilloma virus 16 (anti-HPV-16) and anti-human Papilloma virus 18 (anti-HPV-18) antibodies
Timeframe: At Months 0, 6, 7, 12, 18 and 24
Number of subjects reporting solicited local and general symptoms
Timeframe: Within 7 days after each and any vaccination
Number of subjects reporting unsolicited adverse events (AE)
Timeframe: Within 30 days after any vaccination
Number of subjects reporting serious adverse events (SAE)
Timeframe: Throughout the study period (up to Month 24)
Number of subjects reporting new onset of chronic diseases (NOCDs) and other medically significant conditions (MSCs)
Timeframe: Throughout the study period (up to Month 24)
Outcome of Any Reported Pregnancies
Timeframe: Throughout the study period (up to Month 24)
Number of Subjects Reporting Clinically Relevant Abnormalities in Hematological Parameters
Timeframe: At Month 0 and Month 7
Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical Parameters
Timeframe: At Month 0 and Month 7
Number of subjects reporting abnormal biochemical parameters in urine samples
Timeframe: At Month 0 and Month 7
Interventions:
Biological/vaccine: HPV-16/18 vaccine (Cervarix™)
Biological/vaccine: Aimmugen™
Enrollment:
1046
Observational study model:
Not applicable
Primary completion date:
2009-10-02
Time perspective:
Not applicable
Clinical publications:
Konno R et al. (2009) Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7. Int J Gynecol Cancer. 19(5):905-911.
Konno R et al. (2010) Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Can. 20(3):404-410.
Konno R et al. (2011) Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. Cancer Science. 102(4):877-882.
Konno R et al. Efficacy, immunogenicity and safety of HPV 16/18 AS04-adjuvanted vaccine in Japanese women. Abstract presented at European Research Organization on Genital Infection and Neoplasia 2010 (EUROGIN). Monte Carlo, Monaco, 17-20 February 2010.
Konno R et al. Interim analysis of clinical trial of HPV-16/18-AS04 vaccine in Japan. Abstract presented at the 25th International Papillomavirus Conference, Malmö, Sweden, 8-14 May 2009.
Konno R et al. Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. Abstract presented at European Research Organization on Genital Infection and Neoplasia 2011 (EUROGIN). Lisbon, Portugal, 8-11 May 2011.
Verstraeten T et al. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 26(51):6630–6638.
Medical condition
Infections, Papillomavirus
Product
SB580299
Collaborators
Not applicable
Study date(s)
April 2006 to February 2009
Type
Interventional
Phase
2
Participation criteria
Sex
Female
Age
20 - 25 years
Accepts healthy volunteers
Yes
- Inclusion criteria :
- Subjects who the investigator/co-investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion criteria :
- Subjects who the investigator/co-investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
- A Japanese female subject between, and including, 20 and 25 years of age at the time of the first vaccination.
- Written informed consent obtained from the subject prior to enrolment.
- Healthy subjects as established by medical history and history-oriented clinical examination before entering into the study.
- Subjects must have a negative urine pregnancy test.
- Subjects must be of non-childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.
- Subject must have an intact cervix Exclusion criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine/control within 30 days preceding the first dose of study vaccine/control, or planned use during the study period.
- Pregnant or breastfeeding women. Women must be at least 3 months post-pregnancy and not breastfeeding to enter the study.
- A women planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period, up to 2 months after the last vaccine dose
- previous administration of components of the investigational vaccine
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after the first dose of vaccine. Routine vaccines may be allowed up to 8 days before the first dose of study vaccine.
- Previous vaccination against HPV.
- History of vaccination against hepatitis A or a known clinical history of hepatitis A disease
- Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
- History of allergic disease or reactions likely to be exacerbated by any component of the study vaccines
- Hypersensitivity to latex
- Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality, as determined by previous physical examination or laboratory tests.
- Cancer or autoimmune disease under treatment.
- History of having had colposcopy or has planned a colposcopy to evaluate an abnormal cervical cytology (Pap smear) test.
- Heavy bleeding or heavy vaginal discharge such that a pelvic examination can not be performed
- Acute disease at the time of enrolment.
- Oral temperature >= 37.5°C / axillary temperature > 37.5°C.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2009-10-02
Actual study completion date
2009-10-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website